

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/GB04/005317

International filing date: 17 December 2004 (17.12.2004)

Document type: Certified copy of priority document

Document details: Country/Office: GB
Number: 0329353.7
Filing date: 19 December 2003 (19.12.2003)

Date of receipt at the International Bureau: 09 February 2005 (09.02.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse



PCT/GB 2004 / 0 0 5 3 1 7



INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

Andrew Gersey

Dated 17 January 2005

Journal of Management Studies, 19(6), 701-718.



92

THE PATENT OFFICE

A

19 DEC 2003



19DEC03 E860552-1 D10180
POL/7700 0.00-0329353.7 ACCOUNT CHA

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road
Newport
South Wales
NP10 8QQ

1. Your reference PA0394 GB

19 DEC 2003

0329353.7

2. Patent application number
(The Patent Office will fill this part in)

3. Full name, address and postcode of the or of each applicant (underline all surnames)

AMERSHAM BIOSCIENCES UK LIMITED
Amersham Place
Little Chalfont
Buckinghamshire
HP7 9LL

Patents ADP number (if you know it)

If the applicant is a corporate body, give the country/state of its incorporation

United Kingdom

8331985001

4. Title of the invention

CYTOCHROME C PROTEIN AND ASSAY

5. Name of your agent (if you have one)

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

HAMMER, Catriona, MacLeod; BRYAN Ian, Bennett;
HAMMETT, Audrey, Grace, Campbell and ROLLINS, Anthony, John
Amersham plc
Amersham Place
Little Chalfont
Buckinghamshire HP7 9LL

Patents ADP number (if you know it)

8189375001

6. Priority: Complete this section if you are declaring priority from one or more earlier patent applications, filed in the last 12 months.

Country

Priority application number
(if you know it)

Date of filing
(day / month / year)

7. Divisionals, etc: Complete this section only if this application is a divisional application or resulted from an entitlement dispute (see note f)

Number of earlier UK application

Date of filing
(day / month / year)

8. Is a Patents Form 7/77 (Statement of inventorship and of right to grant of a patent) required in support of this request?

Yes

Answer YES if:

- a) any applicant named in part 3 is not an inventor, or
- b) there is an inventor who is not named as an applicant, or
- c) any named applicant is a corporate body.

Otherwise answer NO (See note d)

Patents Form 1/77

9. Accompanying documents: A patent application must include a description of the invention. Not counting duplicates, please enter the number of pages of each item accompanying this form:

Continuation sheets of this form

Description	17
Claim(s)	6
Abstract	1
Drawing(s)	18 + 18

CF

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for a preliminary examination and search (Patents Form 9/77) 1

Request for a substantive examination (Patents Form 10/77)

Any other documents (please specify)

11. I/We request the grant of a patent on the basis of this application.

Signature(s) HAMMER, Catriona, MacLeod

Date 18 December 2003

12. Name, daytime telephone number and e-mail address, if any, of person to contact in the United Kingdom BRYAN, Ian 01494 542290

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered YES in part 8, a Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- Part 7 should only be completed when a divisional application is being made under section 15(4), or when an application is being made under section 8(3), 12(6) or 37(4) following an entitlement dispute. By completing part 7 you are requesting that this application takes the same filing date as an earlier UK application. If you want the new application to have the same priority date(s) as the earlier UK application, you should also complete part 6 with the priority details.

Cytochrome C Protein and Assay

Technical Field

10 The present invention relates to a cytochrome C-reporter fusion protein construct which targets the mitochondria and has a reduced ability to induce apoptosis in a living cell. The fusion construct of the invention can be used in assays for detecting early events in apoptosis in living cells.

15

Background to the Invention

'Programmed cell death' or apoptosis is a key event in multicellular organisms, defining a genetically encoded cell death program which is morphologically, biochemically and
20 molecularly distinct from necrosis (Vermes et al., J Immunol Meth., (2000) 243, 167-190). The characteristic morphological signs of apoptosis (cellular shrinkage, membrane blebbing, nuclear condensation and fragmentation) are the results of a complex biochemical cascade of events which is an integral part of physiological homeostasis.

25 Apoptosis ensures an equilibrium between cell proliferation and cell death, thus playing a regulatory role in the control of the size of cell populations and tissues. Aberrations in cell death signalling, in membrane or cytoplasmic receptors, or alterations in genes that govern apoptosis are involved in the pathogenesis of congenital malformations and many acquired diseases (Haanen & Vermes, Eur J Obstetr.Gynecol., (1996) 64, 129-133). Too little
30 apoptosis may result in malignancies (Tomlinson & Bodmer, Proc. Natl. Acad.Sci. USA, (1995) 92, 11130- 11134), Leukemias (Sachs, Proc. Natl. Acad. Sci. USA, (1996) 93, 4742- 4749) or the resistance to anticancer therapy (Pahor et al., Lancet, (1996) 348, 493-497). Too much apoptosis can result in immune deficiency (Meyaard et al., Science (1992) 257, 217-219) and degenerative conditions (Griffith et al., Science, (1995) 270,
35 1189-1192).

5 There is therefore considerable interest within the medical, pharmaceutical and toxicological sciences in developing a greater understanding of the events which trigger and regulate apoptosis. Furthermore, there is a need to develop new techniques which can be used to identify, quantify and characterise agents which can modulate this phenomenon.

10

Assays for Detecting Apoptosis

A large number of assays have been developed to detect the onset of programmed cell death (Sgone & Wick, Int Arch Allergy Immunol., (1994) 105, 327-332; Sgone & Gruber, 15 Exp Gerontol., (1998) 33, 525-533). These assays are based upon a wide range of events associated with cell death and have traditionally included light and electron microscopy with vital staining and nuclear dyes. Biochemical methods are often employed, for example based upon DNA laddering or degradation, DNA end labelling techniques (e.g. TUNEL –terminal deoxynucleotide transferase dUTP Nick End labelling), nuclease activity 20 and lactate dehydrogenase enzyme release.

Flow cytometry tends to be the most widely used method (Vermes et al., J Immunol Methods, (2000) 243, 167-190) for detecting and quantifying apoptosis because it is amenable to screening large numbers of cells. This fluorescence - based technique 25 employs vital dyes, antibodies to apoptotic enzymes (e.g. caspases) and single stranded DNA breaks, together with probes for measuring calcium flux and phospholipid redistribution.

Flow cytometry allows *in vivo* analysis of cells in suspension, one at a time, at rates of 30 1000 to 10,000 cells/s. However, one problem with flow cytometry is that it can only be used in cells in suspension, such as liquid cell cultures and cells derived from the hemopoietic system. Furthermore flow cytometry of tissue cells requires physical and enzymatic manipulation to get the cells in suspension, which by itself may trigger apoptosis, necessitating checks by conventional light or fluorescence microscopy.

35

Existing methods are thus based upon late events in apoptosis (e.g. DNA degradation, caspase assays) and many require cellular fixation and staining with specific

5 antibodies/dyes. None of the techniques described above provide a homogeneous living cell assay, based upon the early events in apoptosis, in real time nor discriminate from cellular necrosis. Furthermore, none of these assays are amenable to high throughput live cell screening which is required to test large numbers of compounds for their ability to modulate apoptosis.

10

Cytochrome C Translocation as a Marker for Apoptosis

Cytochrome C is a nuclear encoded protein which is targeted to the mitochondria where it performs its biological function as an electron carrier. The translocation of cytochrome C from the mitochondria to the cytoplasm in response to apoptotic stimuli is an early and critical step in the commitment of the cell to undergo apoptosis (Li et al., Cell (1997) 91, 479-489). Cytochrome C binds strongly to apoptosis protease activation factor -1 (Apaf-1) in the cytosol (Zou et al., Cell (1997) 90, 405-413). In the presence of cofactors the resulting cytochrome C: Apaf-1 assembles into a multimeric 'apoptosome' that binds and activates a protease zymogen, procaspase-9 (Srinivasula et al., Mol. Cell (1998) 1, 949-957). This results in the activation of the 'caspase cascade' whereby many intracellular substrates are cleaved disabling important cellular processes and breaking down structural components of the cell (Slee et al., J Cell.Biol. (1999) 144, 281-292; Skulachev, FEBS Lett., (1998) 423, 275-280). A schematic diagram illustrating the mitochondrial role in apoptosis is shown in Figure 1.

Recent *in vitro* studies (Kluck et al., J. Biol. Chem., (2000), 275, 16127-16133; Yu et al., J.Biol.Chem., (2001), 276, 1304-13038) have identified the molecular determinants involved in the cytochrome C: Apaf-1 interaction. Horse cytochrome C has been shown to be highly homologous to human cytochrome C and can initiate caspase activation, whereas yeast cytochrome C did not measurably bind to Apaf-1 nor activate caspase (Yu et al., J Biol Chem., (2001) 276, 13034-13038). These studies focussed on the key differences between horse and yeast cytochrome C and used site directed mutagenesis to generate mutant variants which were subsequently analysed with respect to their ability to activate caspase. The results from this *in vitro* work indicated that residue 7, 25, 39, 62-65 and 72 were critical amino acids for cytochrome C:Apaf-1 interaction. Notably the mutation K72A showed no detectable binding or caspase-9 activation. While the mutation of lysine

- 5 72 to alanine abolished the interaction between cytochrome C and Apaf1, respiratory function of cytochrome C was unaffected.

Although the authors demonstrated reduced binding to Apaf-1 and caspase-9 activation *in vitro* it is not known whether the cytochrome C mutant proteins would behave in a similar
10 manner in living cells, targeting the mitochondria and not inducing apoptosis.

Recent reports by Abdullaev et al. (Biochem J. (2002) 362, 749-754), again based on *in vitro* experiments, indicate that the horse K72 mutants described by Yu et al. (J Biol Chem., (2001) 276, 13034-13038) show the same level of caspase activation as the wild-type
15 protein if present at 2-12 fold higher concentrations than the wild type protein. In contrast, the authors reported that a horse K4E cytochrome C mutant was inactive in activating caspase and conclude that this mutant, rather than K72 mutants, would be a good candidate for *in vivo* knock-in studies on the role of cytochrome C in apoptosis.

20 Fluorescent Proteins

The use of Green Fluorescent Protein (GFP) derived from *Aequorea victoria* is now well known for research into many cellular and molecular-biological processes. Cytochrome C-GFP fusions have been used in studies on apoptosis. Thus Heiskanen et al. (J Biol Chem.,
25 (1999) 274, 5654-5658) expressed a cytochrome C-GFP fusion, based upon rat cytochrome c, in rat pheochromocytoma-6 (PC6) cells. Induction of apoptosis by staurosporine led to release of the fusion from the mitochondria which was accompanied by mitochondrial depolarisation.

30 Goldstein et al., (Nat Cell Bio., (2000) 2, 156-160) demonstrated mitochondrial localisation of a cytochrome C-GFP fusion, based upon human cytochrome C, over-expressed in HeLa cells. A range of apoptotic inducers were shown to cause rapid release of cytochrome C-GFP.

5 Problem to be Addressed

There is a need to develop sensitive assays which are amenable to high throughput screening in living cells and which allow detection and analysis in real time of the early events in apoptosis.

10

While over-expression of cytochrome C in cells has been demonstrated, the resulting high levels of protein lead to apoptosis and cell death, necessitating the use of complex inducible/transient systems for studies involving up-regulation of cytochrome C levels (Chandra et al., J Biol Chem. (2002) 277, 50842-50854). To date, it has not been possible to generate stable cell lines over-expressing this protein which could be reliably used for screening purposes.

15

There is thus a need for a cytochrome C protein which, when coupled to a reporter group to form a fusion construct, can be expressed in cells to provide stable cell lines. The resulting construct can act as a biosensor within the cells for early events in the induction or repression of apoptosis. Stable cell lines overexpressing such constructs are suitable for high throughput screening purposes to identify agents which modulate apoptosis.

20

The present invention addresses this problem and provides a fusion construct which has no observable toxicity to cells and acts as a biosensor to permit the detection of early events in apoptosis in living cells. The stably transformed cells of the invention can still undergo apoptosis due to the presence of endogenous cytochrome C, thus allowing detection and determination of a second apoptotic signalling event whether up or downstream of the cytochrome C translocation.

30

35

5

Summary of the Invention

In a first aspect of the present invention there is provided a cytochrome C-reporter fusion protein construct comprising a modified cytochrome C protein or any functional analogue thereof derived from wild type cytochrome C, wherein the modified cytochrome C targets
10 the mitochondria and has a reduced ability to induce apoptosis in a living cell.

A reporter is to be understood to be any group that is detectable due to its radioactive, fluorescent or luminescent properties or is localisable by a detectable moiety such as a labelled antibody or specific binding compound.

15

Preferably, the modified cytochrome C binds apoptosis protease activation factor-1 (Apaf-1) at least 10 times less than wild type cytochrome C. More preferably, the modified cytochrome C binds Apaf-1 at least 100 times less than wild type cytochrome C. Most preferably, the modified cytochrome C binds Apaf-1 at least 1000 times less than wild type
20 cytochrome C.

Suitably, at least one of the amino acids of the modified cytochrome C at positions 4, 7, 8, 25, 39, 62, 63, 64, 65 and 72 has been mutated relative to the wild type cytochrome C.

25 Suitably, the modified cytochrome C has an amino substitution or substitutions selected from the group consisting of K4E, K72A, K72L, K72R, K72G, K72X, E62N, K7E-K8E, K25P-K39H, K7A-E62N-K25P, K7A-E62N-K39H, K7E-K8E-E62N, K7A-K25P-E62N, K7A-E62N-K25P-K39H, E62N-T63N-L64M-M65S, K7E-K8E-E62N-K25P-K39H, K7E-K8E-K25P-E62N-T63N-L64M-M65S, K7E-K8E-K39H-E62N-T63N-L64M-M65S and K7E-K8E-
30 K25P-K39H-E62N-T63N-L64M-M65S.

Preferably, the modified cytochrome C comprises the amino acid substitution selected from the group consisting of K7E-K8E-E62N-K25P-K39H, K7E-K8E-K25P-E62N-T63N-L64M-M65S, K7E-K8E-K39H-E62N-T63N-L64M-M65S and K7E-K8E-K25P-K39H-E62N-T63N-
35 L64M-M65S.

- 5 More preferably, the modified cytochrome C comprises the amino acid substitution selected from the group consisting of K72A, K72L, K72R, K72G and K72X, wherein X represents trimethylation. Most preferably, the modified cytochrome C comprises the amino acid substitution K72A or K72L.
- 10 Preferably, modified cytochrome C comprises the amino acid substitution K4E.

Suitably, the reporter is a fluorescent protein or a functional analogue thereof.

- 15 It will be understood by the person skilled in the art that a functional analogue of a fluorescent protein will include, but is not limited to, any detectable fluorescent protein fragment formed in a protein fragment complementation assay as described, for example, in US 6,270,964, US 6,428,951 and US 6,294,330.

- 20 Preferably, the fluorescent protein of the present invention is a Green Fluorescent Protein (GFP) derived from *Aequoria Victoria*, *Renilla reniformis* or other members of the class *Anthozoa* (Labas et al., Proc.Natl.Acad.Sci, (2002), 99, 4256-4261).

- 25 US 6172188 describes variant GFPs wherein the amino acid in position 1 preceding the chromophore has been mutated to provide an increase in fluorescence intensity. These mutants result in a substantial increase in the intensity of fluorescence of GFP without shifting the excitation and emission maxima. F64L-GFP has been shown to yield an approximate 6-fold increase in fluorescence at 37 °C due to shorter chromophore maturation time.

- 30 One mutant, commonly termed Enhanced Green Fluorescent Protein (EGFP), contains the mutations F64L and S65T (Cormack, B.P. et al., Gene, (1996), 173, 33-38). EGFP has been optimised for expression in mammalian systems, having been constructed with preferred mammalian codons.

- 35 Suitably, the fluorescent protein is selected from the group consisting of Green Fluorescent Protein (GFP), Yellow Fluorescent Protein (YFP), Blue Fluorescent Protein (BFP), Cyan Fluorescent Protein (CFP), Red Fluorescent Protein (RFP), Enhanced Green Fluorescent

- 5 Protein (EGFP) and Emerald. Preferably, the fluorescent protein is either EGFP or Emerald.

10 GB 2374868 describes GFP derivatives having a triple mutation at F64, S65/E222 and S175 which exhibit enhanced fluorescence relative to wild type GFP when expressed in non-homologous cells at temperatures above 30°C and when excited at about 490 nm. Mutant GFPs produced using the method of the invention provide a means for detecting GFP reporters in mammalian cells at lower levels of expression and/or increased sensitivity relative to wild type GFP.

- 15 Preferably, the GFP of the present invention comprises
- i) an amino acid substitution at position F64L;
 - ii) an amino acid substitution at position S175G; and
 - iii) an amino acid substitution at position E222G.

- 20 In a preferred embodiment the fusion construct is either SEQ ID NO: 4 or SEQ ID NO: 6.

In one embodiment, the reporter is localisable by a detectable luminescent, fluorescent or radio-active moiety. Thus, for example, the reporter comprises an immunogenic motif and the detectable moiety may be a luminescent, fluorescent or radio-actively labelled antibody.

25

Suitably, the reporter comprises a FLAG™, HA, HIS, c-Myc, VSV-G, V5 or a HSV (Sigma-Aldrich) epitope which is localisable by specific labelled antibodies.

- 30 In another embodiment, the reporter comprises a cysteine-rich motif and the detectable moiety comprises a labelled biarsenical compound as described by Griffin et al., Science (1998), 281, 269-272) and in US 6,054,271, US 6,008,378 and US5,932,474.

In a second aspect of the present invention, there is provided a nucleotide sequence encoding a protein fusion construct as hereinbefore described.

5 Preferably the nucleotide sequence is SEQ ID NO: 3 or SEQ ID NO: 5.

In a third aspect of the present invention, there is provided a nucleic acid construct comprises a suitable control region and the nucleotide sequence as hereinbefore described, the sequence being under the control of the control region.

10

Suitably, the nucleic acid construct is under the control of a promoter selected from the group consisting of native cytochrome C promoter, mammalian constitutive promoter, mammalian regulatory promoter, human ubiquitin C promoter, viral promoter, SV40 promoter, CMV promoter, yeast promoter, filamentous fungal promoter and bacterial

15 promoter.

Preferably, the promoter is the CMV or the SV40 promoter. More preferably, the promoter is the human ubiquitin C promoter.

20 In a fourth aspect of the present invention, there is provided a replicable vector comprising a nucleic acid construct as hereinbefore described.

Suitably, the vector is a plasmid vector as described by Makrides (Prot Expression & Purif. (1999) 17, 183-202).

25

Preferably the vector is a viral vector. Suitable viral vectors for use in the invention are described, for example, by Ng et al., Hum Gene Ther. (2000) 11, 693-699 and include cytomegalovirus, Herpes simplex virus, Epstein-Barr virus, Simian virus 40, Bovine papillomavirus, Adeno-associated virus, Adenovirus, Vaccina virus and Baculovirus vector.

30

In a fifth aspect of the present invention, there is provided a host cell stably transformed with a nucleic acid construct as hereinbefore described.

In a sixth aspect of the present invention, there is provided a host cell transiently

35 transformed with a nucleic acid construct as hereinbefore described.

- 5 Suitably, the host cell is selected from the group consisting of plant, insect, nematode, bird, fish and mammalian cell. Preferably the cell is a human cell. More preferably the human cell is selected from the group consisting of Hek, Hela, U2OS and MCF-7. Most preferably the cell is Hek cell line 293 (Hek293).
- 10 Suitably, the host cell is capable of expressing the fusion protein as hereinbefore described.

In a seventh aspect of the present invention, there is provided a method for detecting apoptosis in a living cell comprising the steps of

- 15 i) culturing a cell transformed to over-express a fusion construct as hereinbefore described;
- ii) determining the localisation of the fusion construct within the cell with time;

wherein a change in localisation of the fusion construct within the cell is indicative of
20 apoptosis.

In an eighth aspect of the present invention, there is provided a method for measuring the effect an agent has upon modulating apoptosis in a living cell comprising the steps of

- 25 i) culturing a cell transformed to over-express a fusion construct as hereinbefore described;
- ii) determining the localisation of the construct within the cell;
- iii) treating the cell with the agent and determining the localisation of the construct within the cell;

wherein any difference in the localisation of the construct within the cell relative to control
30 cells untreated with the agent is indicative of the effect the agent has upon modulating apoptosis.

In a ninth aspect of the present invention, there is provided a method for measuring the effect an agent has upon modulating apoptosis in a living cell comprising the steps of

- 35 i) culturing a first cell and a second cell which both over-express a fusion construct as hereinbefore described;

- 5 ii) treating the first cell with the agent and determining the localisation of the construct within the first cell;
 iii) determining the localisation of the construct within the second cell which has not been treated with the agent;

10 wherein any difference in the localisation of the construct within the first cell and second cell is indicative of the effect the agent has upon modulating apoptosis.

In a tenth aspect of the present invention, there is provided a method for measuring the effect an agent has upon modulating apoptosis in a living cell comprising the steps of

- 15 i) culturing a cell transformed to over-express a fusion construct as hereinbefore described;
 ii) treating the cell with the agent and determining the localisation of the construct within the cell;
 iii) comparing the localisation of the construct in the presence of the agent with a known value for the localisation of the construct in the absence of the agent;
- 20 wherein any difference in the localisation of the construct within the cell in the presence of the agent and the known value in the absence of the agent is indicative of the effect the agent has upon modulating apoptosis.

25 Suitably, the known value according is stored on a database, such as an electronic or optical database.

Suitably, the localisation of the protein fusion is measured by its luminescence, fluorescence or radioactive properties.

30 The method of the invention is suitable for screening purposes to identify agents which induce or inhibit apoptosis.

In another embodiment of the method of the invention, the localisation of the fusion construct is determined on non-living, fixed cells. Thus, the living cells over-expressing the fusion construct are fixed at specific time points by conventional means and the location of the fusion protein detected using a detectable moiety, such as a labelled antibody or specific binding chemical. In this way, the effect an agent has upon apoptosis can be

35

5 determined by comparing localisation of the fusion construct in the presence and the absence of the agent. Alternatively, the effect that the agent has upon apoptosis can be determined by comparing localisation of the construct in the presence of the agent against a known value (for example, one stored on a database) for localisation in the absence of the agent.

10

Suitably, the agent is a chemical, physical or biological agent. Examples of chemical agents include inorganic and organic compounds, such as drugs, toxins, peptides, proteins and nucleic acids. Physical agents include electromagnetic radiation such as electrical, magnetic and light (UV, gamma, IR, visible) energy. Examples of typical biological agents
15 include viruses, prions, bacteria and fungi which could infect a living cell and modulate apoptosis.

Brief Description of the Drawings

20 Figure 1. Schematic representation depicting the mitochondrial role in apoptosis.

Figure 2 a) InCell Analyzer 3000 images (ca. 40x magnification) showing cytochrome C (K72A-GFP mutant) labelled mitochondria in Hek 293 cells of clone 2B6.

25 Figure 2 b) Confocal microscopic image (ca. 60x) cytochrome C-GFP expression in HeLa cells (from Goldstein et al., (Nat Cell Bio., (2000) 2, 156-160))

Figure 3 a)-c). InCell Analyzer 3000 images showing colocalisation of cytochrome C (K72A mutant)-GFP and Tetramethylrhodamine ethyl ester (TMRE) using dual excitation of
30 cytochrome C and TMRE in Hek 293 cells.

Figure 3 a) Cytochrome C (K72A)-GFP

Figure 3 b) TMRE labelled mitochondria

35

Figure 3 c) overlay of Fig 3a) & 3b) following dual excitation

5 Figure 4. Nucleic acid sequence encoding wild type cytochrome C (SEQ ID NO: 1)

Figure 5. Amino acid sequence of wild type cytochrome C (SEQ ID NO: 2)

Figure 6. Nucleic acid sequence encoding F64L-S175G-E222G-triGFP-cytochrome C
10 (K72A) construct (SEQ ID NO: 3)

Figure 7. Amino acid sequence of F64L-S175G-E222G-triGFP-cytochrome C (K72A)
construct (SEQ ID NO: 4)

15 Figure 8. Nucleic acid sequence encoding cytochrome C (K72A)- F64L-S175G-E222G-
triGFP (SEQ ID NO: 5)

Figure 9. Amino acid sequence of cytochrome C (K72A)- F64L-S175G-E222G-triGFP
(SEQ ID NO: 6)

20

Figure 10. Nucleic acid sequence encoding F64L-S175G-E222G-wild type cytochrome C
construct (SEQ ID NO: 7)

Figure 11. Amino acid sequence of F64L-S175G-E222G wild type cytochrome C
25 construct (SEQ ID NO: 8)

Figure 12. Nucleic acid sequence encoding wild type cytochrome C-F64L-S175G-E222G
tri GFP (SEQ ID NO: 9)

30 Figure 13. Amino acid sequence of wild type cytochrome C-F64L-S175G-E222G tri GFP
(SEQ ID NO: 10)

5

Specific ExamplesExample 1

10

Amplification of the cytochrome C gene, fusion to GFP (F64L-S175G-E222G) and introduction of the K72A (APAF-1 binding) mutation.

15

20

25

30

The fluorescent-cytochrome C mutant fusion proteins of the current invention were produced by joining, in frame, a sequence of the nucleic acid that encodes for the cytochrome C protein to a sequence of the nucleic acid that encodes for a fluorescent protein and then introducing the K72A (APAF- 1 binding) mutation (Kluck et al., J Biol Chem., (2000) 275, 16127-16133)) to the nucleic acid of the fusion construct. A preferred sequence of the human cytochrome C gene is described by Zang and Gerstein (Gene, (2003) 312, 61-72); NCBI Accession number NM_018947. (SEQ ID NO: 1) the encoded protein is shown in SEQ ID NO: 2. Alternative human cytochrome C sequences may be used. In addition, alternative sequences around the start and stop codons of the gene may be used to provide useful restriction enzyme sites for protein fusion. Where such alterations change the amino acid numbering relative to the reference sequence such numbering should be inferred by amino acid alignment with the reference sequence. Preferred sequences of the gene encoding the fluorescent protein include those derived from *Aequorea victoria* published by Chalfie et al, (Science, (1994) 263, 802-5), the GFP-F64L-S175G-E222G mutant (GB Patent 2374868), Emerald (Aurora biosciences), EGFP and related mutants (BD Clontech, Palo Alto, CA), and fluorescent proteins from species of *Anthaxia*, for review see Labas et al, (PNAS, (2002) 99, 4256-4261).

The cytochrome C gene was amplified by RT-PCR from a mixed human cDNA library using primers CYCS1 and CYCS2 or CYCS1 and CYCS3 according to recognised protocols (Sambrook, J. et al (2001) Molecular Cloning - A Laboratory Manual, Cold Spring Harbor Laboratory Press).

- 5 CYCS1; 5'-gttgaattcgaccatgggtgatgttgagaaaggc
 CYCS2; 5'-gttggtgtcgaccttactcattagtagctttttgag
 CYCS3; 5'-gttggtgtcgaccctcattagtagctttttgag

Primer CYCS1 exhibits homology to the 5' region of the cytochrome C gene and contains
 10 both a partial Kozak sequence (Kozak, Cell (1986), 44, 283) and an *Eco*R1 restriction
 enzyme site. Primer CYCS2 exhibits homology to the 3' region of the cytochrome C gene
 and contains a stop codon and *Sal*I restriction enzyme site. Primer CYCS3 exhibits
 homology to the 3' region of the cytochrome C gene and contains a *Sal*I restriction enzyme
 site. The CYCS1-CYCS2 and CYCS1-CYCS3 RT-PCR products were cloned into the
 15 corresponding *Eco*RI and *Sal*I sites of the GFP-fusion vectors pCORON1000-GFP-C1 and
 N1, respectively (Amersham Biosciences, Cardiff, UK) and verified by automated
 sequencing. These vectors contain a CMV promoter to effect the expression of the GFP
 fusion and an SV40 promoter to elicit expression of a neomycin resistance marker. The
 GFP within these vectors is red-shifted and contains the mutations F64L-S175G-E222G as
 20 described in GB 2374868.

Cytochrome C (K72A) mutants were generated with the QuikChange™ site-directed
 mutagenesis kit (Stratagene, La Jolla, Ca, USA) using primers CYCS4 and CYCS5.

- 25 CYCS4; 5'-ggagtatttgagaaatcccgccaagtacatccctggaacaa
 CYCS5; 5'-ttgtccagggatgtacttggcgggattctccaaataactcc

After sequence verification the pCORON1000-GFP-wild type cytochrome C and K72A
 mutant fusion constructs were sub-cloned into the vector pCORON2100 using the
 30 restriction enzymes *Nhe*I and *Not*I. pCORON2100 contains a CMV promoter and an IRES
 element to drive bicistronic expression of the GFP-fusion protein and a neomycin
 resistance marker.

The nucleic acid and amino acid sequences of the GFP-cytochrome C constructs obtained
 35 are shown in Figures 6 to 13 (SEQ ID NOS: 3-10)

5 Example 2

Influence of cytochrome C-K72A (APAF-1 binding) mutation upon GFP-fusion protein stable cell line generation in mammalian cells.

10 Plasmid DNA to be used for transfection was prepared for all constructs using the HiSpeed plasmid purification kit (Qiagen, Westberg, NL). In addition to the constructs in example 1, pCORON1000-GFP and pCORON2100-GFP were used as selection controls. DNA was diluted to 100 ng. μl^{-1} in 18-Megohm water (Sigma, Dorset, UK) and 1 μg used for
transfections. For 50-80% confluency on the day of transfection, Hek293 cells were plated
15 at a density of 5×10^4 /well in 6-well plates and incubated overnight. A 1:3 (1 μg : 3 μl) ratio of DNA to FuGene6 reagent (Roche Diagnostics, Basel, Switzerland) was used for each transient transfection reaction; 3 μl FuGene6 was added to 87 μl serum-free DMEM medium (Sigma) (containing penicillin/streptomycin, L-glutamine [Invitrogen, Carlsbad, CA]) and gently tapped to mix, then 10 μl (1 μg) construct DNA was added and again gently
20 mixed. The FuGene6 : DNA complex was incubated at room temperature for 40 minutes and added dropwise, with gentle mixing, directly to the cells without changing the medium. The plates were then gently swirled for even distribution. Cells were monitored for expression after 24 and 48 hours using a Nikon Eclipse TE200 epifluorescent microscope (Nikon, Melville, NY). Cells were passed into 15cm diameter plates and after 24 hours
25 placed under selection with geneticin (G418, 250 ng. μl^{-1} ; Sigma). The concentration of geneticin was increased incrementally to 500 ng. μl^{-1} over the following 5-7 days. Selection continued for around 10 days or until cells in the mock-transfected control plates had died. Cloning rings were then used to isolate surviving colonies and cells were expanded through 96-well, 24-well and 6-well plates. Where appropriate second and third rounds of
30 clonal selection were applied.

After the first round of clonal selection surviving cells were visible for transfections containing pCORON1000-GFP, pCORON2100-GFP and the pCORON2100-GFP-N and -C cytochrome C (K72A) mutant plasmids. No surviving colonies were obtained from cells
35 transfected with other plasmid constructs.

5 Results

Expression studies of this mutated cDNA were performed in pCORON2100 (Amersham Biosciences) in order to utilise the IRES element and facilitate the generation of stable cell lines. A "mixed population" stably expressing cell line under selection with geneticin G418 was continuously cultured for 3 weeks. 15 single clonal cell lines were then isolated.

10

Hek293 cells containing the pCORON2100-GFP-cytochrome C (K72A) mutants were shown to exhibit stable expression during continuous culture over a 4 month period. The mitochondrial localisation of the reporter fusion proteins was confirmed during this period by co-localisation with the known mitochondrial marker mitotracker red (Molecular Probes, Eugene, OR) using a Microsystems LSM (Zeiss, Thornwood, NY) and a high throughput laser scanning confocal microscope (INCell Analyzer 3000, Amersham Biosciences).

15

The expression results from one of these stable clones (2B6), using the InCell Analyzer 3000 (Amersham Biosciences, UK) laser scanning confocal imaging system, are shown below in Figure 2. As can be seen from Figure 2a the localisation pattern of expressed cytochrome C-GFP closely resembles that observed by Goldstein et al., (Nat Cell Bio., (2000) 2, 156-160), using a confocal microscope, reproduced in Figure 2b. As expected, the fusion protein demonstrates nuclear exclusion and localises to mitochondria, the cytochrome C-GFP displaying a punctuate pattern of fluorescence (Figure 2a).

20

Figures 3a and 3b show localisation of the fusion protein construct (a) and the mitochondrial stain TMRE (b) at a concentration of 40nM in the mitochondria of Hek 293 cells. Dual excitation of the cytochrome C-GFP and TMRE in the InCell Analyzer demonstrates co-localisation (Figure 3c).

25

30

Claims

1. A cytochrome C-reporter fusion protein construct comprising a modified cytochrome C protein or any functional analogue thereof derived from wild type cytochrome C, wherein said modified cytochrome C targets the mitochondria and has a reduced ability to induce apoptosis in a living cell.
2. The fusion construct of claim 1, wherein the modified cytochrome C binds apoptosis protease activation factor-1 (Apaf-1) at least ten times less than wild type cytochrome C.
3. The fusion construct of claim 1 or 2, wherein the modified cytochrome C binds apoptosis protease activation factor-1 (Apaf-1) at least 100 times less than wild type cytochrome C.
4. The fusion construct of any preceding claim, wherein the modified cytochrome C binds apoptosis protease activation factor-1 (Apaf-1) at least 1000 times less than wild type cytochrome C.
5. The fusion construct of any preceding claim, wherein at least one of the amino acids of the modified cytochrome C at positions 4, 7, 8, 25, 39, 62, 63, 64, 65 and 72 has been mutated relative to the wild type cytochrome C.
6. The fusion construct of claim 5, wherein the modified cytochrome C has an amino substitution or substitutions selected from the group consisting of K4E, K72A, K72L, K72R, K72G, K72X, E62N, K7E-K8E, K25P-K39H, K7A-E62N-K25P, K7A-E62N-K39H, K7E-K8E-E62N, K7A-K25P-E62N, K7A-E62N-K25P-K39H, E62N-T63N-L64M-M65S, K7E-K8E-E62N-K25P-K39H, K7E-K8E-K25P-E62N-T63N-L64M-M65S, K7E-K8E-K39H-E62N-T63N-L64M-M65S and K7E-K8E-K25P-K39H-E62N-T63N-L64M-M65S.
7. The fusion construct of claim 6, wherein the modified cytochrome C comprises the amino acid substitution selected from the group consisting of K7E-K8E-E62N-K25P-K39H, K7E-K8E-K25P-E62N-T63N-L64M-M65S, K7E-K8E-K39H-E62N-T63N-L64M-M65S and K7E-K8E-K25P-K39H-E62N-T63N-L64M-M65S.

- 5 8. The fusion construct of claim 6, wherein the modified cytochrome C comprises the amino acid substitution selected from the group consisting of K72A, K72L, K72R, K72G and K72X, wherein X represents trimethylation.
- 10 9. The fusion construct of either of claims 6 or 8, wherein the modified cytochrome C comprises the amino acid substitution K72A or K72L.
10. The fusion construct of claim 6, wherein the modified cytochrome C comprises the amino acid substitution K4E.
- 15 11. The fusion construct of any preceding claim, wherein the reporter is a fluorescent protein or a functional analogue thereof.
- 20 12. The fusion construct of claim 11, wherein said fluorescent protein is selected from the group consisting of Green Fluorescent Protein (GFP), Yellow Fluorescent Protein (YFP), Blue Fluorescent Protein (BFP), Cyan Fluorescent Protein (CFP), Red Fluorescent Protein (RFP), Enhanced Green Fluorescent Protein (EGFP) and Emerald.
13. The fusion construct of either of claims 11 or 12, wherein the fluorescent protein is Enhanced Green Fluorescent Protein or Emerald.
- 25 14. The fusion construct of claim 11, wherein the GFP comprises
- i) an amino acid substitution at position F64L;
 - ii) an amino acid substitution at position S175G; and
 - iii) an amino acid substitution at position E222G.
- 30 15. The fusion construct of any preceding claim selected from the group consisting of SEQ ID NO: 4 and SEQ ID NO: 6.
- 35 16. The fusion construct according to any of claims 1 to 10, wherein the reporter is localisable by a detectable luminescent, fluorescent or radio-active moiety.

- 5 17. The fusion construct according to claim 16, wherein the reporter comprises an immunogenic motif.
18. The fusion construct according to claim 15 or 16, wherein the reporter comprises a cysteine-rich motif.
- 10 19. The fusion construct according to claim 16, wherein said detectable moiety comprises a bi- arsenical compound.
- 15 ~~20. The fusion construct according to claim 16, wherein said moiety comprises an antibody.~~
21. A nucleotide sequence encoding a fusion construct of any of the preceding claims.
22. A nucleotide sequence encoding a fusion construct according to claim 15 selected
20 from the group consisting of SEQ ID NO: 3 and SEQ ID NO 5.
23. A nucleic acid construct comprising a suitable control region and a nucleotide sequence according to claim 21 or 22, said sequence being under the control of said control region.
- 25 24. A nucleic acid construct according to claim 23 being under the control of a promoter selected from the group consisting of native cytochrome C promoter, mammalian constitutive promoter, mammalian regulatory promoter, human ubiquitin C promoter, viral promoter, SV40 promoter, CMV promoter, yeast promoter, filamentous fungal promoter
30 and bacterial promoter.
25. A nucleic acid construct according to claim 24, wherein said viral promoter is the CMV or the SV40 promoter.
- 35 26. A nucleic acid construct according to claim 24, wherein the promoter is the human ubiquitin C promoter.

- 5 27. A replicable vector comprising a nucleic acid construct according to any of claims 23 to 26.
28. The replicable vector of claim 27, wherein said vector is a plasmid vector.
- 10 29. The replicable vector of claim 27, wherein the vector is a viral vector.
30. The replicable vector of claim 29, wherein said viral vector is selected from the group consisting of cytomegalovirus, Herpes simplex virus, Epstein-Barr virus, Simian virus 40, Bovine papillomavirus, Adeno-associated virus, Adenovirus, Vaccina virus and
- 15 Baculovirus vector.
31. A host cell stably transformed with a nucleic acid construct according to any of claims 23 to 26.
- 20 32. A host cell transiently transformed with a nucleic acid construct according to any of claims 23 to 26.
33. The host cell of claims 31 or 32 selected from the group consisting of plant, insect, nematode, bird, fish and mammalian cell.
- 25 34. The host cell of claim 33, wherein said mammalian cell is a human cell.
35. The host cell of claim 34, wherein said human cell is selected from the group consisting of Hek, HeLa, U2OS and MCF-7.
- 30 36. The host cell of claim 35, wherein said Hek cell is Hek293.
37. The host cell according to any of claims 31 to 36 capable of expressing the fusion protein of any of claims 1 to 20.
- 35 38. A method for detecting apoptosis in a living cell comprising the steps of

- 5 i) culturing a cell transformed to over-express a fusion construct according to any of claims 1 to 20;
 ii) determining the localisation of the fusion construct within the cell with time;
 wherein a change in localisation of the fusion construct within the cell is indicative of
 10 apoptosis.

39. A method for measuring the effect that an agent has upon modulating apoptosis in a living cell comprising the steps of
 15 i) culturing a cell transformed to over-express a fusion construct according to any of claims 1 to 20;
 ii) determining the localisation of said construct within the cell;
 iii) treating the cell with said agent and determining the localisation of the construct within the cell;
 wherein any difference in the localisation of the construct within the cell relative to
 20 control cells untreated with the agent is indicative of the effect that the agent has upon modulating apoptosis.

40. A method for measuring the effect an agent has upon modulating apoptosis in a living cell comprising the steps of
 25 i) culturing a first cell and a second cell which both over-express a fusion construct according to any of claims 1 to 20;
 ii) treating said first cell with said agent and determining the localisation of said construct within the first cell;
 iii) determining the localisation of the construct within said second cell which has not
 30 been treated with the agent;
 wherein any difference in the localisation of the construct within the first cell and second cell is indicative of the effect that the agent has upon modulating apoptosis.

41. A method for measuring the effect an agent has upon modulating apoptosis in a
 35 living cell comprising the steps of
 i) culturing a cell transformed to over-express a fusion construct according to any of claims 1 to 20;

5 ii) treating said cell with said agent and determining the localisation of the construct within the cell;

 iii) comparing the localisation of the construct in the presence of the agent with a known value for the localisation of the construct in the absence of the agent;

 wherein any difference in the localisation of the construct within the cell in the presence of
10 the agent and said known value in the absence of the agent is indicative of the effect that the agent has upon modulating apoptosis.

~~42.~~ The method according to claim 41, wherein the known value is stored on a database.

15 43. The method according to any of claims 38 to 42, wherein the localisation of said fusion construct is measured by its luminescence, fluorescence or radioactive properties.

44. The method according to any of claims 39 to 43, wherein said agent induces apoptosis.

20 45. The method according to any of claims 39 to 43, wherein the agent inhibits apoptosis.

25 46. The method according to any of claims 38 to 45, wherein the localisation of the protein fusion is determined following fixation of the cells.

47. The method according to any of claims 38 to 46, where the agent is a chemical, physical or biological agent.

5

Abstract


10

The present invention relates to a a cytochrome C-reporter fusion protein construct comprising a modified cytochrome C protein which targets the mitochondria and has a reduced ability to induce apoptosis in a living cell. The invention also relates to nucleic acid constructs encoding such protein fusions and cells stably transfected with such constructs. The stably transfected cells of the invention can be used in assays to detect apoptosis.

15

20

25






Figure 1



1




Figure 2 a)




Figure 2 b)






Figure 3 a)




Figure 3 b)



4/18




Figure 3c



Figure 4: SEQ ID NO: 1 - Wild Type Cytochrome C (NM_018947)

1	Met Gly Asp Val Glu Lys Gly Lys Lys Ile Phe Ile Met Lys Cys Ser
	ATG GGT GAT GTT GAG AAA GGC AAG AAG ATT TTT ATT ATG AAG TGT TCC
49	Gln Cys His Thr Val Glu Lys Gly Gly Lys His Lys Thr Gly Pro Asn
	CAG TGC CAC ACC GTT GAA AAG GGA GGC AAG CAC AAG ACT GGG CCA AAT
97	Leu His Gly Leu Phe Gly Arg Lys Thr Gly Gln Ala Pro Gly Tyr Ser
	CTC CAT GGT CTC TTT GGG CGG AAG ACA GGT CAG GCC CCT GGA TAC TCT
145	Tyr Thr Ala Ala Asn Lys Asn Lys Gly Ile Ile Trp Gly Glu Asp Thr
	TAC ACA GCC GCC AAT AAG AAC AAA GGC ATC ATC TGG GGA GAG GAT ACA
193	Leu Met Glu Tyr Leu Glu Asn Pro Lys Lys Tyr Ile Pro Gly Thr Lys
	CTG ATG GAG TAT TTG GAG AAT CCC AAG AAG TAC ATC CCT GGA ACA AAA
241	Met Ile Phe Val Gly Ile Lys Lys Lys Glu Glu Arg Ala Asp Leu Ile
	ATG ATC TTT GTC GGC ATT AAG AAG AAG GAA GAA AGG GCA GAC TTA ATA
289	Ala Tyr Leu Lys Lys Ala Thr Asn Glu
	GCT TAT CTC AAA AAA GCT ACT AAT GAG



Figure 5. SEQ ID NO: 2 - Wild type Cytochrome C (NM_018947)

1
Met Gly Asp Val Glu Lys Gly Lys Lys Ile Phe Ile Met Lys Cys Ser
17
Gln Cys His Thr Val Glu Lys Gly Gly Lys His Lys Thr Gly Pro Asn
33
Leu His Gly Leu Phe Gly Arg Lys Thr Gly Gln Ala Pro Gly Tyr Ser
49
Tyr Thr Ala Ala Asn Lys Asn Lys Gly Ile Ile Trp Gly Glu Asp Thr
65
Leu Met Glu Tyr Leu Glu Asn Pro Lys Lys Tyr Ile Pro Gly Thr Lys
81
Met Ile Phe Val Gly Ile Lys Lys Lys Glu Glu Arg Ala Asp Leu Ile
97
Ala Tyr Leu Lys Lys Ala Thr Asn Glu



Figure 6. SEQ ID NO: 3 TriGFP-cytochrome C K72A

1	Met Ser Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile Leu Val
	ATG AGT AAA GGA GAA GAA CTT TTC ACT GGA GTT GTC CCA ATT CTT GTT
49	Glu Leu Asp Gly Asp Val Asn Gly His Lys Phe Ser Val Ser Gly Glu
	GAA TTA GAT GGT GAT GTT AAT GGG CAC AAA TTT TCT GTC AGT GGA GAG
97	Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe Ile Cys
	GGT GAA GGT GAT GCA ACA TAC GGA AAA CTT ACC CTT AAA TTT ATT TGC
145	Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr Leu
	ACT ACT GGA AAA CTA CCT GTT CCA TGG CCA ACA CTT GTC ACT ACT CTC
193	Ser Tyr Gly Val Gln Cys Phe Ser Arg Tyr Pro Asp His Met Lys Arg
	TCT TAT GGT GTT CAA TGC TTT TCA AGA TAC CCA GAT CAT ATG AAA CGG
241	His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln Glu Arg
	CAT GAC TTT TTC AAG AGT GCC ATG CCC GAA GGT TAT GTA CAG GAA AGA
289	Thr Ile Phe Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala Glu Val
	ACT ATA TTT TTC AAA GAT GAC GGG AAC TAC AAG ACA CGT GCT GAA GTC
337	Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys Gly Ile
	AAG TTT GAA GGT GAT ACC CTT GTT AAT AGA ATC GAG TTA AAA GGT ATT
385	Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Leu Glu Tyr Asn
	GAT TTT AAA GAA GAT GGA AAC ATT CTT GGA CAC AAA TTG GAA TAC AAC
433	Tyr Asn Ser His Asn Val Tyr Ile Met Ala Asp Lys Gln Lys Asn Gly
	TAT AAC TCA CAC AAT GTA TAC ATC ATG GCA GAC AAA CAA AAG AAT GGA
481	Ile Lys Val Asn Phe Lys Ile Arg His Asn Ile Glu Asp Gly Gly Val
	ATC AAA GTT AAC TTC AAA ATT AGA CAC AAC ATT GAA GAT GGA GGC GTT
529	Gln Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly Pro
	CAA CTA GCA GAC CAT TAT CAA CAA AAT ACT CCA ATT GGC GAT GGC CCT
577	Val Leu Leu Pro Asp Asn His Tyr Leu Ser Thr Gln Ser Ala Leu Ser
	GTC CTT TTA CCA GAC AAC CAT TAC CTG TCC ACA CAA TCT GCC CTT TCG
625	Lys Asp Pro Asn Glu Lys Arg Asp His Met Val Leu Leu Gly Phe Val
	AAA GAT CCC AAC GAA AAG AGA GAC CAC ATG GTC CTT CTT GGC TTT GTA
673	Thr Ala Ala Gly Ile Thr His Gly Met Asp Glu Leu Tyr Lys Leu Glu
	ACA GCT GCT GGG ATT ACA CAT GGC ATG GAT GAA CTA TAC AAA CTC GAG
721	Asn Ser Thr Met Gly Asp Val Glu Lys Gly Lys Lys Ile Phe Ile Met
	AAT TCG ACC ATG GGT GAT GTT GAG AAA GGC AAG AAG ATT TTT ATT ATG
769	Lys Cys Ser Gln Cys His Thr Val Glu Lys Gly Gly Lys His Lys Thr
	AAG TGT TCC CAG TGC CAC ACC GTT GAA AAG GGA GGC AAG CAC AAG ACT
817	Gly Pro Asn Leu His Gly Leu Phe Gly Arg Lys Thr Gly Gln Ala Pro
	GGG CCA AAT CTC CAT GGT CTC TTT GGG CGG AAG ACA GGT CAG GCC CCT
	Gly Tyr Ser Tyr Thr Ala Ala Asn Lys Asn Lys Gly Ile Ile Trp Gly



8/18

865 GGA TAC TCT TAC ACA GCC GCC AAT AAG AAC AAA GGC ATC ATC TGG GGA
Glu Asp Thr Leu Met Glu Tyr Leu Glu Asn Pro Ala Lys Tyr Ile Pro
913 GAG GAT ACA CTG ATG GAG TAT TTG GAG AAT CCC GCC AAG TAC ATC CCT
Gly Thr Lys Met Ile Phe Val Gly Ile Lys Lys Lys Glu Glu Arg Ala
961 GGA ACA AAA ATG ATC TTT GTC GGC ATT AAG AAG AAG GAA GAA AGG GCA
Asp Leu Ile Ala Tyr Leu Lys Lys Ala Thr Asn Glu
1009 GAC TTA ATA GCT TAT CTC AAA AAA GCT ACT AAT GAG



Figure 7: SEQ ID NO: 4 - triGFP-cytochrome C K72A

1
Met Ser Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile Leu Val
17
Glu Leu Asp Gly Asp Val Asn Gly His Lys Phe Ser Val Ser Gly Glu
33
Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe Ile Cys
49
Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr Leu
65
Ser Tyr Gly Val Gln Cys Phe Ser Arg Tyr Pro Asp His Met Lys Arg
81
His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln Glu Arg
97
Thr Ile Phe Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala Glu Val
113
Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys Gly Ile
129
Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Leu Glu Tyr Asn
145
Tyr Asn Ser His Asn Val Tyr Ile Met Ala Asp Lys Gln Lys Asn Gly
161
Ile Lys Val Asn Phe Lys Ile Arg His Asn Ile Glu Asp Gly Gly Val
177
Gln Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly Pro
193
Val Leu Leu Pro Asp Asn His Tyr Leu Ser Thr Gln Ser Ala Leu Ser
209
Lys Asp Pro Asn Glu Lys Arg Asp His Met Val Leu Leu Gly Phe Val
225
Thr Ala Ala Gly Ile Thr His Gly Met Asp Glu Leu Tyr Lys Leu Glu
241
Asn Ser Thr Met Gly Asp Val Glu Lys Gly Lys Lys Ile Phe Ile Met
257
Lys Cys Ser Gln Cys His Thr Val Glu Lys Gly Gly Lys His Lys Thr
273
Gly Pro Asn Leu His Gly Leu Phe Gly Arg Lys Thr Gly Gln Ala Pro
289
Gly Tyr Ser Tyr Thr Ala Ala Asn Lys Asn Lys Gly Ile Ile Trp Gly
305
Glu Asp Thr Leu Met Glu Tyr Leu Glu Asn Pro Ala Lys Tyr Ile Pro
321
Gly Thr Lys Met Ile Phe Val Gly Ile Lys Lys Lys Glu Glu Arg Ala
337
Asp Leu Ile Ala Tyr Leu Lys Lys Ala Thr Asn Glu



Figure 8. SEQ ID NO: 5 - Cytochrome C (K72A)-triGFP

Met Gly Asp Val Glu Lys Gly Lys Lys Ile Phe Ile Met Lys Cys Ser
 1 ATG GGT GAT GTT GAG AAA GGC AAG AAG ATT TTT ATT ATG AAG TGT TCC

Gln Cys His Thr Val Glu Lys Gly Gly Lys His Lys Thr Gly Pro Asn
 49 CAG TGC CAC ACC GTT GAA AAG GGA GGC AAG CAC AAG ACT GGG CCA AAT

Leu His Gly Leu Phe Gly Arg Lys Thr Gly Gln Ala Pro Gly Tyr Ser
 97 CTC CAT GGT CTC TTT GGG CGG AAG ACA GGT CAG GCC CCT GGA TAC TCT

Tyr Thr Ala Ala Asn Lys Asn Lys Gly Ile Ile Trp Gly Glu Asp Thr
 145 TAC ACA GCC GCC AAT AAG AAC AAA GGC ATC ATC TGG GGA GAG GAT ACA

Leu Met Glu Tyr Leu Glu Asn Pro Ala Lys Tyr Ile Pro Gly Thr Lys
 193 CTG ATG GAG TAT TTG GAG AAT CCC GCC AAG TAC ATC CCT GGA ACA AAA

Met Ile Phe Val Gly Ile Lys Lys Lys Glu Glu Arg Ala Asp Leu Ile
 241 ATG ATC TTT GTC GGC ATT AAG AAG AAG GAA GAA AGG GCA GAC TTA ATA

Ala Tyr Leu Lys Lys Ala Thr Asn Glu Gly Arg Pro Gly Met Ser Lys
 289 GCT TAT CTC AAA AAA GCT ACT AAT GAG GGT CGA CCC GGG ATG AGT AAA

Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile Leu Val Glu Leu Asp
 337 GGA GAA GAA CTT TTC ACT GGA GTT GTC CCA ATT CTT GTT GAA TTA GAT

Gly Asp Val Asn Gly His Lys Phe Ser Val Ser Gly Glu Gly Glu Gly
 385 GGT GAT GTT AAT GGG CAC AAA TTT TCT GTC AGT GGA GAG GGT GAA GGT

Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe Ile Cys Thr Thr Gly
 433 GAT GCA ACA TAC GGA AAA CTT ACC CTT AAA TTT ATT TGC ACT ACT GGA

Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr Leu Ser Tyr Gly
 481 AAA CTA CCT GTT CCA TGG CCA ACA CTT GTC ACT ACT CTC TCT TAT GGT

Val Gln Cys Phe Ser Arg Tyr Pro Asp His Met Lys Arg His Asp Phe
 529 GTT CAA TGC TTT TCA AGA TAC CCA GAT CAT ATG AAA CGG CAT GAC TTT

Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln Glu Arg Thr Ile Phe
 577 TTC AAG AGT GCC ATG CCC GAA GGT TAT GTA CAG GAA AGA ACT ATA TTT

Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala Glu Val Lys Phe Glu
 625 TTC AAA GAT GAC GGG AAC TAC AAG ACA CGT GCT GAA GTC AAG TTT GAA

Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys Gly Ile Asp Phe Lys
 673 GGT GAT ACC CTT GTT AAT AGA ATC GAG TTA AAA GGT ATT GAT TTT AAA

Glu Asp Gly Asn Ile Leu Gly His Lys Leu Glu Tyr Asn Tyr Asn Ser
 721 GAA GAT GGA AAC ATT CTT GGA CAC AAA TTG GAA TAC AAC TAT AAC TCA

His Asn Val Tyr Ile Met Ala Asp Lys Gln Lys Asn Gly Ile Lys Val
 769 CAC AAT GTA TAC ATC ATG GCA GAC AAA CAA AAG AAT GGA ATC AAA GTT

Asn Phe Lys Ile Arg His Asn Ile Glu Asp Gly Gly Val Gln Leu Ala
 817 AAC TTC AAA ATT AGA CAC AAC ATT GAA GAT GGA GGC GTT CAA CTA GCA

Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly Pro Val Leu Leu



11/18

865 GAC CAT TAT CAA CAA AAT ACT CCA ATT GGC GAT GGC CCT GTC CTT TTA

Pro Asp Asn His Tyr Leu Ser Thr Gln Ser Ala Leu Ser Lys Asp Pro
913 CCA GAC AAC CAT TAC CTG TCC ACA CAA TCT GCC CTT TCG AAA GAT CCC

Asn Glu Lys Arg Asp His Met Val Leu Leu Gly Phe Val Thr Ala Ala
961 AAC GAA AAG AGA GAC CAC ATG GTC CTT CTT GGC TTT GTA ACA GCT GCT

Gly Ile Thr His Gly Met Asp Glu Leu Tyr Lys
1009 GGG ATT ACA CAT GGC ATG GAT GAA CTA TAC AAA



Figure 9. SEQ ID NO: 6 - Cytochrome C (K72A)-triGFP

1
Met Gly Asp Val Glu Lys Gly Lys Lys Ile Phe Ile Met Lys Cys Ser
17
Gln Cys His Thr Val Glu Lys Gly Gly Lys His Lys Thr Gly Pro Asn
33
Leu His Gly Leu Phe Gly Arg Lys Thr Gly Gln Ala Pro Gly Tyr Ser
49
Tyr Thr Ala Ala Asn Lys Asn Lys Gly Ile Ile Trp Gly Glu Asp Thr
65
Leu Met Glu Tyr Leu Glu Asn Pro Ala Lys Tyr Ile Pro Gly Thr Lys
81
Met Ile Phe Val Gly Ile Lys Lys Lys Glu Glu Arg Ala Asp Leu Ile
97
Ala Tyr Leu Lys Lys Ala Thr Asn Glu Gly Arg Pro Gly Met Ser Lys
113
Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile Leu Val Glu Leu Asp
129
Gly Asp Val Asn Gly His Lys Phe Ser Val Ser Gly Glu Gly Glu Gly
145
Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe Ile Cys Thr Thr Gly
161
Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr Leu Ser Tyr Gly
177
Val Gln Cys Phe Ser Arg Tyr Pro Asp His Met Lys Arg His Asp Phe
193
Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln Glu Arg Thr Ile Phe
209
Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala Glu Val Lys Phe Glu
225
Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys Gly Ile Asp Phe Lys
241
Glu Asp Gly Asn Ile Leu Gly His Lys Leu Glu Tyr Asn Tyr Asn Ser
257
His Asn Val Tyr Ile Met Ala Asp Lys Gln Lys Asn Gly Ile Lys Val
273
Asn Phe Lys Ile Arg His Asn Ile Glu Asp Gly Gly Val Gln Leu Ala
289
Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly Pro Val Leu Leu
305
Pro Asp Asn His Tyr Leu Ser Thr Gln Ser Ala Leu Ser Lys Asp Pro
321
Asn Glu Lys Arg Asp His Met Val Leu Leu Gly Phe Val Thr Ala Ala
337
Gly Ile Thr His Gly Met Asp Glu Leu Tyr Lys



Figure 10. SEQ ID NO: 7 - TriGFP- wild type cytochrome C

1	Met	Ser	Lys	Gly	Glu	Glu	Leu	Phe	Thr	Gly	Val	Val	Pro	Ile	Leu	Val
	ATG	AGT	AAA	GGA	GAA	GAA	CTT	TTC	ACT	GGA	GTT	GTC	CCA	ATT	CTT	GTT
49	Glu	Leu	Asp	Gly	Asp	Val	Asn	Gly	His	Lys	Phe	Ser	Val	Ser	Gly	Glu
	GAA	TTA	GAT	GGT	GAT	GTT	AAT	GGG	CAC	AAA	TTT	TCT	GTC	AGT	GGA	GAG
97	Gly	Glu	Gly	Asp	Ala	Thr	Tyr	Gly	Lys	Leu	Thr	Leu	Lys	Phe	Ile	Cys
	GGT	GAA	GGT	GAT	GCA	ACA	TAC	GGA	AAA	CTT	ACC	CTT	AAA	TTT	ATT	TGC
145	Thr	Thr	Gly	Lys	Leu	Pro	Val	Pro	Trp	Pro	Thr	Leu	Val	Thr	Thr	Leu
	ACT	ACT	GGA	AAA	CTA	CCT	GTT	CCA	TGG	CCA	ACA	CTT	GTC	ACT	ACT	CTC
193	Ser	Tyr	Gly	Val	Gln	Cys	Phe	Ser	Arg	Tyr	Pro	Asp	His	Met	Lys	Arg
	TCT	TAT	GGT	GTT	CAA	TGC	TTT	TCA	AGA	TAC	CCA	GAT	CAT	ATG	AAA	CGG
241	His	Asp	Phe	Phe	Lys	Ser	Ala	Met	Pro	Glu	Gly	Tyr	Val	Gln	Glu	Arg
	CAT	GAC	TTT	TTC	AAG	AGT	GCC	ATG	CCC	GAA	GGT	TAT	GTA	CAG	GAA	AGA
289	Thr	Ile	Phe	Phe	Lys	Asp	Asp	Gly	Asn	Tyr	Lys	Thr	Arg	Ala	Glu	Val
	ACT	ATA	TTT	TTC	AAA	GAT	GAC	GGG	AAC	TAC	AAG	ACA	CGT	GCT	GAA	GTC
337	Lys	Phe	Glu	Gly	Asp	Thr	Leu	Val	Asn	Arg	Ile	Glu	Leu	Lys	Gly	Ile
	AAG	TTT	GAA	GGT	GAT	ACC	CTT	GTT	AAT	AGA	ATC	GAG	TTA	AAA	GGT	ATT
385	Asp	Phe	Lys	Glu	Asp	Gly	Asn	Ile	Leu	Gly	His	Lys	Leu	Glu	Tyr	Asn
	GAT	TTT	AAA	GAA	GAT	GGA	AAC	ATT	CTT	GGA	CAC	AAA	TTG	GAA	TAC	AAC
433	Tyr	Asn	Ser	His	Asn	Val	Tyr	Ile	Met	Ala	Asp	Lys	Gln	Lys	Asn	Gly
	TAT	AAC	TCA	CAC	AAT	GTA	TAC	ATC	ATG	GCA	GAC	AAA	CAA	AAG	AAT	GGA
481	Ile	Lys	Val	Asn	Phe	Lys	Ile	Arg	His	Asn	Ile	Glu	Asp	Gly	Gly	Val
	ATC	AAA	GTT	AAC	TTC	AAA	ATT	AGA	CAC	AAC	ATT	GAA	GAT	GGA	GGC	GTT
529	Gln	Leu	Ala	Asp	His	Tyr	Gln	Gln	Asn	Thr	Pro	Ile	Gly	Asp	Gly	Pro
	CAA	CTA	GCA	GAC	CAT	TAT	CAA	CAA	AAT	ACT	CCA	ATT	GGC	GAT	GGC	CCT
577	Val	Leu	Leu	Pro	Asp	Asn	His	Tyr	Leu	Ser	Thr	Gln	Ser	Ala	Leu	Ser
	GTC	CTT	TTA	CCA	GAC	AAC	CAT	TAC	CTG	TCC	ACA	CAA	TCT	GCC	CTT	TCG
625	Lys	Asp	Pro	Asn	Glu	Lys	Arg	Asp	His	Met	Val	Leu	Leu	Gly	Phe	Val
	AAA	GAT	CCC	AAC	GAA	AAG	AGA	GAC	CAC	ATG	GTC	CTT	CTT	GGC	TTT	GTA
673	Thr	Ala	Ala	Gly	Ile	Thr	His	Gly	Met	Asp	Glu	Leu	Tyr	Lys	Leu	Glu
	ACA	GCT	GCT	GGG	ATT	ACA	CAT	GGC	ATG	GAT	GAA	CTA	TAC	AAA	CTC	GAG
721	Asn	Ser	Thr	Met	Gly	Asp	Val	Glu	Lys	Gly	Lys	Lys	Ile	Phe	Ile	Met
	AAT	TCG	ACC	ATG	GGT	GAT	GTT	GAG	AAA	GGC	AAG	AAG	ATT	TTT	ATT	ATG
769	Lys	Cys	Ser	Gln	Cys	His	Thr	Val	Glu	Lys	Gly	Gly	Lys	His	Lys	Thr
	AAG	TGT	TCC	CAG	TGC	CAC	ACC	GTT	GAA	AAG	GGA	GGC	AAG	CAC	AAG	ACT
817	Gly	Pro	Asn	Leu	His	Gly	Leu	Phe	Gly	Arg	Lys	Thr	Gly	Gln	Ala	Pro
	GGG	CCA	AAT	CTC	CAT	GGT	CTC	TTT	GGG	CGG	AAG	ACA	GGT	CAG	GCC	CCT
	Gly	Tyr	Ser	Tyr	Thr	Ala	Ala	Asn	Lys	Asn	Lys	Gly	Ile	Ile	Trp	Gly



14/18

865	GGA TAC TCT TAC ACA GCC GCC AAT AAG AAC AAA GGC ATC ATC TGG GGA
	Glu Asp Thr Leu Met Glu Tyr Leu Glu Asn Pro Lys Lys Tyr Ile Pro
913	GAG GAT ACA CTG ATG GAG TAT TTG GAG AAT CCC AAG AAG TAC ATC CCT
	Gly Thr Lys Met Ile Phe Val Gly Ile Lys Lys Lys Glu Glu Arg Ala
961	GGA ACA AAA ATG ATC TTT GTC GGC ATT AAG AAG AAG GAA GAA AGG GCA
	Asp Leu Ile Ala Tyr Leu Lys Lys Ala Thr Asn Glu
1009	GAC TTA ATA GCT TAT CTC AAA AAA GCT ACT AAT GAG



.

Figure 11. SEQ ID NO: 8 - TriGFP-wild type cytochrome C

1
Met Ser Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile Leu Val
17
Glu Leu Asp Gly Asp Val Asn Gly His Lys Phe Ser Val Ser Gly Glu
33
Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe Ile Cys
49
Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr Leu
65
Ser Tyr Gly Val Gln Cys Phe Ser Arg Tyr Pro Asp His Met Lys Arg
81
His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln Glu Arg
97
Thr Ile Phe Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala Glu Val
113
Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys Gly Ile
129
Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Leu Glu Tyr Asn
145
Tyr Asn Ser His Asn Val Tyr Ile Met Ala Asp Lys Gln Lys Asn Gly
161
Ile Lys Val Asn Phe Lys Ile Arg His Asn Ile Glu Asp Gly Gly Val
177
Gln Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly Pro
193
Val Leu Leu Pro Asp Asn His Tyr Leu Ser Thr Gln Ser Ala Leu Ser
209
Lys Asp Pro Asn Glu Lys Arg Asp His Met Val Leu Leu Gly Phe Val
225
Thr Ala Ala Gly Ile Thr His Gly Met Asp Glu Leu Tyr Lys Leu Glu
241
Asn Ser Thr Met Gly Asp Val Glu Lys Gly Lys Lys Ile Phe Ile Met
257
Lys Cys Ser Gln Cys His Thr Val Glu Lys Gly Gly Lys His Lys Thr
273
Gly Pro Asn Leu His Gly Leu Phe Gly Arg Lys Thr Gly Gln Ala Pro
289
Gly Tyr Ser Tyr Thr Ala Ala Asn Lys Asn Lys Gly Ile Ile Trp Gly
305
Glu Asp Thr Leu Met Glu Tyr Leu Glu Asn Pro Lys Lys Tyr Ile Pro
321
Gly Thr Lys Met Ile Phe Val Gly Ile Lys Lys Lys Glu Glu Arg Ala
337
Asp Leu Ile Ala Tyr Leu Lys Lys Ala Thr Asn Glu



Figure 12. SEQ ID NO: 9 - Wild type Cytochrome C-triGFP

	Met	Gly	Asp	Val	Glu	Lys	Gly	Lys	Lys	Ile	Phe	Ile	Met	Lys	Cys	Ser
1	ATG	GGT	GAT	GTT	GAG	AAA	GGC	AAG	AAG	ATT	TTT	ATT	ATG	AAG	TGT	TCC
	Gln	Cys	His	Thr	Val	Glu	Lys	Gly	Gly	Lys	His	Lys	Thr	Gly	Pro	Asn
49	CAG	TGC	CAC	ACC	GTT	GAA	AAG	GGA	GGC	AAG	CAC	AAG	ACT	GGG	CCA	AAT
	Leu	His	Gly	Leu	Phe	Gly	Arg	Lys	Thr	Gly	Gln	Ala	Pro	Gly	Tyr	Ser
97	CTC	CAT	GGT	CTC	TTT	GGG	CGG	AAG	ACA	GGT	CAG	GCC	CCT	GGA	TAC	TCT
	Tyr	Thr	Ala	Ala	Asn	Lys	Asn	Lys	Gly	Ile	Ile	Trp	Gly	Glu	Asp	Thr
145	TAC	ACA	GCC	GCC	AAT	AAG	AAC	AAA	GGC	ATC	ATC	TGG	GGA	GAG	GAT	ACA
	Leu	Met	Glu	Tyr	Leu	Glu	Asn	Pro	Lys	Lys	Tyr	Ile	Pro	Gly	Thr	Lys
193	CTG	ATG	GAG	TAT	TTG	GAG	AAT	CCC	AAG	AAG	TAC	ATC	CCT	GGA	ACA	AAA
	Met	Ile	Phe	Val	Gly	Ile	Lys	Lys	Lys	Glu	Glu	Arg	Ala	Asp	Leu	Ile
241	ATG	ATC	TTT	GTC	GGC	ATT	AAG	AAG	AAG	GAA	GAA	AGG	GCA	GAC	TTA	ATA
	Ala	Tyr	Leu	Lys	Lys	Ala	Thr	Asn	Glu	Gly	Arg	Pro	Gly	Met	Ser	Lys
289	GCT	TAT	CTC	AAA	AAA	GCT	ACT	AAT	GAG	GGT	CGA	CCC	GGG	ATG	AGT	AAA
	Gly	Glu	Glu	Leu	Phe	Thr	Gly	Val	Val	Pro	Ile	Leu	Val	Glu	Leu	Asp
337	GGA	GAA	GAA	CTT	TTC	ACT	GGA	GTT	GTC	CCA	ATT	CTT	GTT	GAA	TTA	GAT
	Gly	Asp	Val	Asn	Gly	His	Lys	Phe	Ser	Val	Ser	Gly	Glu	Gly	Glu	Gly
385	GGT	GAT	GTT	AAT	GGG	CAC	AAA	TTT	TCT	GTC	AGT	GGA	GAG	GGT	GAA	GGT
	Asp	Ala	Thr	Tyr	Gly	Lys	Leu	Thr	Leu	Lys	Phe	Ile	Cys	Thr	Thr	Gly
433	GAT	GCA	ACA	TAC	GGA	AAA	CTT	ACC	CTT	AAA	TTT	ATT	TGC	ACT	ACT	GGA
	Lys	Leu	Pro	Val	Pro	Trp	Pro	Thr	Leu	Val	Thr	Thr	Leu	Ser	Tyr	Gly
481	AAA	CTA	CCT	GTT	CCA	TGG	CCA	ACA	CTT	GTC	ACT	ACT	CTC	TCT	TAT	GGT
	Val	Gln	Cys	Phe	Ser	Arg	Tyr	Pro	Asp	His	Met	Lys	Arg	His	Asp	Phe
529	GTT	CAA	TGC	TTT	TCA	AGA	TAC	CCA	GAT	CAT	ATG	AAA	CGG	CAT	GAC	TTT
	Phe	Lys	Ser	Ala	Met	Pro	Glu	Gly	Tyr	Val	Gln	Glu	Arg	Thr	Ile	Phe
577	TTC	AAG	AGT	GCC	ATG	CCC	GAA	GGT	TAT	GTA	CAG	GAA	AGA	ACT	ATA	TTT
	Phe	Lys	Asp	Asp	Gly	Asn	Tyr	Lys	Thr	Arg	Ala	Glu	Val	Lys	Phe	Glu
625	TTC	AAA	GAT	GAC	GGG	AAC	TAC	AAG	ACA	CGT	GCT	GAA	GTC	AAG	TTT	GAA
	Gly	Asp	Thr	Leu	Val	Asn	Arg	Ile	Glu	Leu	Lys	Gly	Ile	Asp	Phe	Lys
673	GGT	GAT	ACC	CTT	GTT	AAT	AGA	ATC	GAG	TTA	AAA	GGT	ATT	GAT	TTT	AAA
	Glu	Asp	Gly	Asn	Ile	Leu	Gly	His	Lys	Leu	Glu	Tyr	Asn	Tyr	Asn	Ser
721	GAA	GAT	GGA	AAC	ATT	CTT	GGA	CAC	AAA	TTG	GAA	TAC	AAC	TAT	AAC	TCA
	His	Asn	Val	Tyr	Ile	Met	Ala	Asp	Lys	Gln	Lys	Asn	Gly	Ile	Lys	Val
769	CAC	AAT	GTA	TAC	ATC	ATG	GCA	GAC	AAA	CAA	AAG	AAT	GGA	ATC	AAA	GTT
	Asn	Phe	Lys	Ile	Arg	His	Asn	Ile	Glu	Asp	Gly	Gly	Val	Gln	Leu	Ala
817	AAC	TTC	AAA	ATT	AGA	CAC	AAC	ATT	GAA	GAT	GGA	GGC	GTT	CAA	CTA	GCA
	Asp	His	Tyr	Gln	Gln	Asn	Thr	Pro	Ile	Gly	Asp	Gly	Pro	Val	Leu	Leu



17/18

865 GAC CAT TAT CAA CAA AAT ACT CCA ATT GGC GAT GGC CCT GTC CTT TTA

Pro Asp Asn His Tyr Leu Ser Thr Gln Ser Ala Leu Ser Lys Asp Pro
913 CCA GAC AAC CAT TAC CTG TCC ACA CAA TCT GCC CTT TCG AAA GAT CCC

Asn Glu Lys Arg Asp His Met Val Leu Leu Gly Phe Val Thr Ala Ala
961 AAC GAA AAG AGA GAC CAC ATG GTC CTT CTT GGC TTT GTA ACA GCT GCT

Gly Ile Thr His Gly Met Asp Glu Leu Tyr Lys
1009 GGG ATT ACA CAT GGC ATG GAT GAA CTA TAC AAA



Figure 13. SEQ ID NO: 10 - Wild Type Cytochrome C-triGFP

1
Met Gly Asp Val Glu Lys Gly Lys Lys Ile Phe Ile Met Lys Cys Ser
17
Gln Cys His Thr Val Glu Lys Gly Gly Lys His Lys Thr Gly Pro Asn
33
Leu His Gly Leu Phe Gly Arg Lys Thr Gly Gln Ala Pro Gly Tyr Ser
49
Tyr Thr Ala Ala Asn Lys Asn Lys Gly Ile Ile Trp Gly Glu Asp Thr
65
Leu Met Glu Tyr Leu Glu Asn Pro Lys Lys Tyr Ile Pro Gly Thr Lys
81
Met Ile Phe Val Gly Ile Lys Lys Lys Glu Glu Arg Ala Asp Leu Ile
97
Ala Tyr Leu Lys Lys Ala Thr Asn Glu Gly Arg Pro Gly Met Ser Lys
113
Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile Leu Val Glu Leu Asp
129
Gly Asp Val Asn Gly His Lys Phe Ser Val Ser Gly Glu Gly Glu Gly
145
Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe Ile Cys Thr Thr Gly
161
Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr Leu Ser Tyr Gly
177
Val Gln Cys Phe Ser Arg Tyr Pro Asp His Met Lys Arg His Asp Phe
193
Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln Glu Arg Thr Ile Phe
209
Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala Glu Val Lys Phe Glu
225
Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys Gly Ile Asp Phe Lys
241
Glu Asp Gly Asn Ile Leu Gly His Lys Leu Glu Tyr Asn Tyr Asn Ser
257
His Asn Val Tyr Ile Met Ala Asp Lys Gln Lys Asn Gly Ile Lys Val
273
Asn Phe Lys Ile Arg His Asn Ile Glu Asp Gly Gly Val Gln Leu Ala
289
Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly Pro Val Leu Leu
305
Pro Asp Asn His Tyr Leu Ser Thr Gln Ser Ala Leu Ser Lys Asp Pro
321
Asn Glu Lys Arg Asp His Met Val Leu Leu Gly Phe Val Thr Ala Ala
337
Gly Ile Thr His Gly Met Asp Glu Leu Tyr Lys

THE PATENT OFFICE
21 JAN 2005
Received in Patents
International Unit